5.0
30. Nov. 2024
Aktueller Mitarbeiter, mehr als 3 Jahre
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Great culture, benefits, strong portfolio and nice people. Strong payer coverage for all products.
Kontras
Some growing pains, some favoritism, like most companies. Large geographical responsibilities. Chinese name in USA marketplace . Lack of contracting opportunities for small and mid size oncology providers.